Aurinia Pharmaceuticals(AUPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AUPH Aurinia Pharmaceuticals

Market Closed 06-26 16:00:00 EDT

17.23

-0.32

-1.82%

盘后17.22

-0.01-0.07%

19:56 EDT

High17.72	Low16.75	Vol4.50M
Open17.53	D1 Closing17.55	Amplitude5.53%
Mkt Cap2.22B	Tradable Cap2.21B	Total Shares128.60M
T/O77.21M	T/O Rate3.51%	Tradable Shares128.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AUPH","market":"US","secType":"STK","nameCN":"Aurinia Pharmaceuticals","latestPrice":17.23,"timestamp":1782504000000,"preClose":17.55,"halted":0,"volume":4497560,"hourTrading":{"tag":"盘后","latestPrice":17.2184,"preClose":17.23,"latestTime":"19:56 EDT","volume":972699,"amount":16759365.346444,"timestamp":1782518161341,"change":-0.0116,"changeRate":-0.000673,"amplitude":0.005804},"delay":0,"changeRate":-0.01823361823361825,"floatShares":128000000,"shares":128601671,"eps":2.174691,"marketStatus":"Market Closed","change":-0.32,"latestTime":"06-26 16:00:00 EDT","open":17.53,"high":17.72,"low":16.75,"amount":77211969.24144,"amplitude":0.055271,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.174691,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782720000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":951454800000,"exchange":"NASDAQ","adjPreClose":17.55,"preHourTrading":{"tag":"盘前","latestPrice":17.5,"preClose":17.55,"latestTime":"09:28 EDT","volume":4249,"amount":75103.15701,"timestamp":1782480481279,"change":-0.05,"changeRate":-0.002849,"amplitude":0.142382},"postHourTrading":{"tag":"盘后","latestPrice":17.2184,"preClose":17.23,"latestTime":"19:56 EDT","volume":972699,"amount":16759365.346444,"timestamp":1782518161341,"change":-0.0116,"changeRate":-0.000673,"amplitude":0.005804},"volumeRatio":1.7447648828120936,"impliedVol":0.6097,"impliedVolPercentile":0.8685},"requestUrl":"/m/hq/s/AUPH","defaultTab":"news","newsList":[{"id":"2643215443","title":"13D Filings -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2643215443","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643215443?lang=en_us&edition=fundamental","pubTime":"2026-06-13 06:47","pubTimestamp":1781304420,"startTime":"0","endTime":"0","summary":"These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from June 4 through June 10, 2026. Source: VerityData . Coliseum Capital Management lowered its stake in the educational institution to 971,440 shares. Coliseum did so through the block sale of 3,000,000 Universal Technical Institute shares on June 8 at a price of $41.40 per share and agreed not to sell its remaining shares until the company releases earnings for its fiscal quarter ending on June 30. Following the latest sales, Coliseum Capital Management continues to own a 1.8% stake in","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4204","VAL","LU0211326839.USD","LU0976567544.SGD","BK4515","BK4092","LU1823568750.SGD","BK4139","VSXY","BK4094","AUPH","LU0496365809.HKD","DELL","DLLL","LU1046421795.USD","BK4588","LU2065170008.USD","LU2065171402.SGD","BK4535","BK4585","LU1267930227.SGD","LU0128525689.USD","LU0267386448.USD","LU2065171311.SGD","LU0211326755.USD","LU2065169927.USD","UTI","LU0310800965.SGD","LU0052756011.USD","BK4543","LU1235294995.USD","BK4170"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641120285","title":"Aurinia Data At EULAR 2026 And Insider Buys Shape LUPKYNIS Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2641120285","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641120285?lang=en_us&edition=fundamental","pubTime":"2026-06-07 05:32","pubTimestamp":1780781551,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (NasdaqGM:AUPH) reported new AURORA 1 Phase 3 data at EULAR 2026 showing LUPKYNIS reduced the risk of renal events or death in lupus nephritis.\nThe findings were presented at a major international rheumatology congress, putting fresh clinical evidence for LUPKYNIS in front of global specialists.\nTang Capital Management increased its stake in Aurinia, and senior company executives acquired additional shares.\n\nAurinia focuses on therapies for autoimmune kidney disease,...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/aurinia-data-at-eular-2026-and-insider-buys-shape-lupkynis-o","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/aurinia-data-at-eular-2026-and-insider-buys-shape-lupkynis-o","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641116244","title":"Aurinia Pharmaceuticals holds annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2641116244","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641116244?lang=en_us&edition=fundamental","pubTime":"2026-06-05 04:19","pubTimestamp":1780604370,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals held its annual general meeting on June 3, 2026.Shareholders selected five directors to serve on the board until the 2027 annual meeting.Shareholders backed a non-binding advisory resolution on executive compensation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL3TsxTt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640128154","title":"Aurinia presents new analysis of AURORA 1 Phase 3 study of Lupkynis","url":"https://stock-news.laohu8.com/highlight/detail?id=2640128154","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640128154?lang=en_us&edition=fundamental","pubTime":"2026-06-04 19:05","pubTimestamp":1780571111,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (AUPH) announced that a new analysis of the AURORA 1 Phase 3 study of Lupkynis in the treatment of lupus nephritis is being...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aurinia-presents-new-analysis-of-aurora-1-phase-3-study-of-lupkynis-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aurinia-presents-new-analysis-of-aurora-1-phase-3-study-of-lupkynis-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640151060","title":"Aurinia says Lupkynis cuts renal-related event or death risk 53% in AURORA 1 lupus nephritis analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2640151060","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640151060?lang=en_us&edition=fundamental","pubTime":"2026-06-04 19:01","pubTimestamp":1780570861,"startTime":"0","endTime":"0","summary":"Aurinia disclosed a new analysis from its Phase 3 AURORA 1 study of LUPKYNIS in lupus nephritis, presented at the EULAR 2026 Congress.The analysis showed fewer serious kidney-related outcomes or deaths for patients receiving LUPKYNIS versus placebo.Results also pointed to fewer treatment failures and less worsening of protein in the urine, supporting the drug’s clinical benefit profile.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDLHLxwH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640517521","title":"Lupkynis Associated With a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death","url":"https://stock-news.laohu8.com/highlight/detail?id=2640517521","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640517521?lang=en_us&edition=fundamental","pubTime":"2026-06-04 19:00","pubTimestamp":1780570801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nTUA56HSZP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640902547","title":"Aurinia Pharmaceuticals up 4% in pre-market after insider transactions","url":"https://stock-news.laohu8.com/highlight/detail?id=2640902547","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640902547?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:54","pubTimestamp":1780491252,"startTime":"0","endTime":"0","summary":"Last night, the company stated: “Tang Capital Management announces that on June 2, 2026, it acquired 206,005 common shares of Aurinia Pharmaceutica...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aurinia-pharmaceuticals-up-4-in-pre-market-after-insider-transactions-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aurinia-pharmaceuticals-up-4-in-pre-market-after-insider-transactions-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640903191","title":"Aurinia Pharmaceuticals CEO Buys $12.5 Million Worth of Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2640903191","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640903191?lang=en_us&edition=fundamental","pubTime":"2026-06-03 18:10","pubTimestamp":1780481412,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals  Chief Executive Kevin Tang purchased about 815,000 shares in the company for a combined $12.5 million, a Wednesday filing with the US Securities and Exchange Commission showed.Shares were acquired between May 29 and June 2 across several transactions at prices ranging from $15.28 to $15.35 apiece, the filing showed.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640097303","title":"Tang Capital Management, Llc Files Early Warning Report Respecting Aurinia Pharmaceuticals Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2640097303","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640097303?lang=en_us&edition=fundamental","pubTime":"2026-06-03 12:44","pubTimestamp":1780461864,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nTUA73P2S9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640927032","title":"Aurinia CEO Kevin Tang reports buying $13.12 million of common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2640927032","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640927032?lang=en_us&edition=fundamental","pubTime":"2026-06-03 09:55","pubTimestamp":1780451720,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals: CEO Kevin Tang reported net purchases of 814,606 common shares at about $15.28-$15.35 a share.Holdings rose to 13,044,106 common shares, held indirectly through affiliated funds.The funds also sold 10,000 short put options, creating potential obligation to buy 1 million shares at $15 through Jan. 15, 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL98Wzr1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Aurinia CEO Kevin Tang reports buying $13.12 million of common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638682685","title":"Aurinia issues corporate presentation outlining LUPKYNIS growth strategy, aritinercept development plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2638682685","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638682685?lang=en_us&edition=fundamental","pubTime":"2026-05-28 00:26","pubTimestamp":1779899167,"startTime":"0","endTime":"0","summary":"Aurinia outlined plans to drive further growth for LUPKYNIS while advancing aritinercept, a dual BAFF/APRIL inhibitor candidate for autoimmune diseases.Q1 2026 total revenue rose 24% to USD 77.7 million; net product sales increased 23% to USD 73.6 million.Q1 2026 net income climbed 48% to USD 34.4 million; diluted EPS increased to USD 0.25 from USD 0.16.Operating cash flow improved to USD 32.6 million from USD 1.3 million.2026 guidance: total revenue USD 315 million to USD 325 million; net product sales USD 305 million to USD 315 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief on May 27, 2026, and is solely responsible for the informati","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL11mfZ3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636485673","title":"Aurinia completes tender offer for Kezar, wins 80% of shares tendered","url":"https://stock-news.laohu8.com/highlight/detail?id=2636485673","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636485673?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:33","pubTimestamp":1779193990,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals completed its tender offer for Kezar Life Sciences, with 5,927,580 shares tendered, representing 80.24% of Kezar’s outstanding shares.The tendered shares had an aggregate value of about $41.23 million.The offer price was $6.96 in cash per share, with one non-transferable contingent value right issued for each share tendered.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL63J81g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH","BK4139","KZR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634228749","title":"Aurinia Pharmaceuticals Completes Acquisition of Kezar Life Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2634228749","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634228749?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:59","pubTimestamp":1778507988,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals ( ($AUPH) ) just unveiled an update. On May 8, 2026, Aurinia Pharma U.S., Inc. completed a tender offer to acquire approxim...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aurinia-pharmaceuticals-completes-acquisition-of-kezar-life-sciences?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aurinia-pharmaceuticals-completes-acquisition-of-kezar-life-sciences?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634282997","title":"Aurinia Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2634282997","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634282997?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:31","pubTimestamp":1778506285,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings SummaryAurinia Pharmaceuticals Inc AUPH.OQ reported quarterly adjusted earnings of 25 cents per share for the quar","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O1FN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634284076","title":"Aurinia completes Kezar acquisition at $6.96 per share plus CVR","url":"https://stock-news.laohu8.com/highlight/detail?id=2634284076","media":"Reuters","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634284076?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:21","pubTimestamp":1778505698,"startTime":"0","endTime":"0","summary":"Aurinia completed acquisition of Kezar Life Sciences via tender offer priced at USD 6.96 per share in cash plus one contingent value right.Offer expired May 8, 2026 with 5,927,580 shares tendered, representing about 80.24% of outstanding shares.Merger closed May 11, 2026, leaving Kezar as a wholly owned subsidiary of Aurinia’s US unit.Outstanding Kezar options vested at closing, with in-the-money awards converted into cash based on spread to cash price plus CVRs; out-of-the-money options were cancelled.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Se","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL8X8FY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KZR","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634407620","title":"Kezar Q1 net loss narrows to $5.8 million; operating loss narrows to $7.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634407620","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634407620?lang=en_us&edition=fundamental","pubTime":"2026-05-11 18:08","pubTimestamp":1778494118,"startTime":"0","endTime":"0","summary":"Kezar Life Sciences posted a net loss of USD 5.8 million for the quarter ended March 31, 2026, narrowing from USD 16.6 million a year earlier.Operating loss narrowed to USD 7.4 million from USD 17.7 million, with total operating expenses dropping to USD 7.4 million from USD 17.7 million.Research and development expense fell to USD 1.5 million from USD 12.2 million, while general and administrative expense edged down to USD 5.2 million from USD 5.5 million.Interest income slipped to USD 0.6 million from USD 1.4 million, while the quarter included a USD 1 million gain on sale of a nonfinancial asset.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kezar Life Sciences Inc. published the original content used to generate this news brief via","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL3B2hdJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AUPH","KZR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633142755","title":"Aurinia publishes corporate presentation on LUPKYNIS growth strategy in lupus nephritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2633142755","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633142755?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:35","pubTimestamp":1778157331,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals outlined continued commercial growth plans for lupus nephritis drug LUPKYNIS, positioning it as only FDA-approved calcineurin inhibitor for the indication.For three months ended March 31, 2026, total revenue was $77.7 million, net product sales were $73.6 million, net income was $34.4 million.Operating cash flow was $32.6 million for the quarter, versus $1.3 million a year earlier.2026 guidance set total revenue at $315 million to $325 million, net product sales at $305 million to $315 million.Pipeline update highlighted aritinercept, a dual BAFF/APRIL inhibitor, as development focus for potential autoimmune disease treatment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL9xTLBr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633238144","title":"Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q1 EPS $0.25, vs. FactSet Est of $0.20","url":"https://stock-news.laohu8.com/highlight/detail?id=2633238144","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633238144?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:13","pubTimestamp":1778155990,"startTime":"0","endTime":"0","summary":"Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q1 EPS $0.25, vs. FactSet Est of $0.20","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633144841","title":"Aurinia Q1 net income rises 48% to $34.4 million; revenue climbs 24% to $77.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633144841","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633144841?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:03","pubTimestamp":1778155419,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals posted Q1 total revenue of USD 77.7 million, up 24%, while diluted EPS climbed 56% to USD 0.25.Net income rose 48% to USD 34.4 million, while cash flows from operating activities more than doubled to USD 32.6 million.Net product sales increased 23% to USD 73.6 million, while license, collaboration and royalty revenue rose 64% to USD 4.1 million.Cash, cash equivalents, restricted cash and investments totaled USD 378.8 million at March 31, down from USD 398 million at Dec. 31, 2025, after USD 53.7 million of financing outflows that included USD 36.2 million of share repurchases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news bri","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL9XDJwm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633417141","title":"BRIEF-Aurinia Pharmaceuticals Q1 Product Revenue USD 73.563 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633417141","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633417141?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:00","pubTimestamp":1778155246,"startTime":"0","endTime":"0","summary":"BRIEF-Aurinia Pharmaceuticals Q1 Product Revenue USD 73.563 Million\n\n\nMay 07 (Reuters) - Aurinia Pharmaceuticals Q1 net income USD 34.355 million.\n\nQ1 operating expenses USD 36.283 million\nQ1 pretax profit USD 43.925 million\nQ1 operating income USD 41.422 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX7DC125:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.auriniapharma.com","stockEarnings":[{"period":"1week","weight":0.0468},{"period":"1month","weight":0.1088},{"period":"3month","weight":0.2074},{"period":"6month","weight":0.0603},{"period":"1year","weight":0.9965},{"period":"ytd","weight":0.0803}],"compareEarnings":[{"period":"1week","weight":-0.0238},{"period":"1month","weight":-0.0286},{"period":"3month","weight":0.1497},{"period":"6month","weight":0.056},{"period":"1year","weight":0.1914},{"period":"ytd","weight":0.069}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.071692},{"month":2,"riseRate":0.416667,"avgChangeRate":0.005745},{"month":3,"riseRate":0.5,"avgChangeRate":0.089864},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.004824},{"month":5,"riseRate":0.5,"avgChangeRate":-0.007754},{"month":6,"riseRate":0.5,"avgChangeRate":-0.008151},{"month":7,"riseRate":0.636364,"avgChangeRate":0.041551},{"month":8,"riseRate":0.545455,"avgChangeRate":-0.014541},{"month":9,"riseRate":0.454545,"avgChangeRate":0.063835},{"month":10,"riseRate":0.583333,"avgChangeRate":0.048963},{"month":11,"riseRate":0.583333,"avgChangeRate":0.036405},{"month":12,"riseRate":0.416667,"avgChangeRate":0.092842}],"exchange":"NASDAQ","name":"Aurinia Pharmaceuticals","nameEN":"Aurinia Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aurinia Pharmaceuticals(AUPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aurinia Pharmaceuticals(AUPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aurinia Pharmaceuticals,AUPH,Aurinia Pharmaceuticals股票,Aurinia Pharmaceuticals股票老虎,Aurinia Pharmaceuticals股票老虎国际,Aurinia Pharmaceuticals行情,Aurinia Pharmaceuticals股票行情,Aurinia Pharmaceuticals股价,Aurinia Pharmaceuticals股市,Aurinia Pharmaceuticals股票价格,Aurinia Pharmaceuticals股票交易,Aurinia Pharmaceuticals股票购买,Aurinia Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aurinia Pharmaceuticals(AUPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aurinia Pharmaceuticals(AUPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}